The DOI matches its Crossref record; 393 of the 393 references it cites were found in a registry or an index.
Trial watch: Oncolytic viruses for cancer therapy
Open accessAbstract
Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterparts. From a conceptual standpoint, oncolytic viruses differ from so-called "oncotropic viruses" in that only the former are able to kill cancer cells, even though both display a preferential tropism for malignant tissues. Of note, such a specificity can originate at several different steps of the viral cycle, including the entry of virions (transductional specificity) as well as their intracellular survival and replication (post-transcriptional and transcriptional specificity). During the past two decades, a large array of replication-competent and replication-incompetent oncolytic viruses has been developed and engineered to express gene products that would specifically promote the death of infected (cancer) cells. However, contrarily to long-standing beliefs, the antineoplastic activity of oncolytic viruses is not a mere consequence of the cytopathic effect, i.e., the lethal outcome of an intense, productive viral infection, but rather involves the elicitation of an antitumor immune response. In line with this notion, oncolytic viruses genetically modified to drive the local production of immunostimulatory cytokines exert more robust therapeutic effects than their non-engineered counterparts. Moreover, the efficacy of oncolytic virotherapy is significantly improved by some extent of initial immunosuppression (facilitating viral replication and spread) followed by the administration of immunostimulatory molecules (boosting antitumor immune responses). In this Trial Watch, we will discuss the results of recent clinical trials that have evaluated/are evaluating the safety and antineoplastic potential of oncolytic virotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarinella, F., Calistri, A., Sette, P., Palù, G., & Parolin, C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302770 · Cited by 30
RetractedNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Self-citationTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Self-citationPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citationPhagocytosis of Microbes: Complexity in Action
Underhill, D. M., & Ozinsky, A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.103001.114744 · Cited by 1,124
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Self-citationDecoding cell death signals in liver inflammation
Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.033 · Cited by 1,022
Self-citationMarkert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Self-citationStojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 842
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834
Self-citationConsensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationStojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Self-citationZamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Self-citationThe secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Self-citationVascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Self-citationTherapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Hecht, J. R., Bedford, R. A., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., & Freeman, S. M. (2003) · PubMed · Cited by 494
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Self-citationOncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101136398 · Cited by 465
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Self-citationChiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432
Viral Control of Mitochondrial Apoptosis
Galluzzi, L., Brenner, C., Morselli, E., Touat, Z., & Kroemer, G. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000018 · Cited by 427
Self-citationMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Self-citationPhase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
DeWeese, T. L., van der Poel, H. G., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U. M., DeJong, R., Detorie, N. A., Rodríguez, R., et al. (2001) · PubMed · Cited by 385
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Self-citationTargeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21335 · Cited by 378
Self-citationReprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
Munich, S., Sobo-Vujanovic, A., Buchser, W. J., Beer-Stolz, D., & Vujanovic, N. L. (2012) · OncoImmunology · doi:10.4161/onci.20897 · Cited by 360
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040557897 · Cited by 332
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Papanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Oncolytic viruses as therapeutic cancer vaccines
Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-103 · Cited by 324
Dingli, D., Peng, K.-W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., & Russell, S. J. (2004) · Blood · doi:10.1182/blood-2003-07-2233 · Cited by 320
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Freytag, S. O., Khil, M. S., Stricker, H. J., et al. (2002) · PubMed · Cited by 310
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309
Antonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Self-citation(2000) · PubMed · Cited by 295
miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Galluzzi, L., Morselli, E., Vitale, I., Kepp, O., Senovilla, L., Criollo, A., Servant, N., Paccard, C., Hupé, P., Robert, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3112 · Cited by 280
Self-citationCTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
Jiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., Xu, J., Kondo, Y., Bekele, B. N., Colman, H., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm102 · Cited by 278
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Russell, S. J., Federspiel, M. J., Peng, K.-W., Tong, C., Dingli, D., Morice, W. G., Lowe, V., O'Connor, M. K., Kyle, R. A., Leung, N., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.003 · Cited by 274
Freytag, S. O., Stricker, H. J., Pegg, J., Paielli, D. L., Pradhan, D. G., Peabody, J. O., de Peralta‐Venturina, M., Xia, X., Brown, S., Lü, M., et al. (2003) · PubMed · Cited by 271
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Self-citationNemunaitis, J., Tong, A. W., Nemunaitis, M., Senzer, N., Phadke, A. P., Bedell, C., Adams, N., Zhang, Y.-A., Maples, P. B., Chen, S., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.262 · Cited by 265
Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0196 · Cited by 259
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Breitbach, C. J., Arulanandam, R., De Silva, N., Thorne, S. H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2687 · Cited by 258
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Self-citationVasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Self-citationRamesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242
Reddy, P. S., Burroughs, K. D., Hales, L. M., Ganesh, S., Jones, B. H., Idamakanti, N., Hay, C., Li, S. S., Skele, K. L., Vasko, A.-J., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm198 · Cited by 242
Xia, Z.-J., Chang, J.-H., Zhang, L., et al. (2004) · PubMed · Cited by 241
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Vidal, L., Pandha, H. S., Yap, T. A., White, C. L., Twigger, K., Vile, R. G., Melcher, A., Coffey, M., Harrington, K. J., & DeBono, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0524 · Cited by 237
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Self-citationSystemic Delivery of Oncolytic Viruses: Hopes and Hurdles
Ferguson, M. S., Lemoine, N. R., & Wang, Y. (2012) · Advances in Virology · doi:10.1155/2012/805629 · Cited by 231
Engineering microRNA responsiveness to decrease virus pathogenicity
Kelly, E. J., Hadac, E. M., Greiner, S., & Russell, S. J. (2008) · Nature Medicine · doi:10.1038/nm.1776 · Cited by 217
Obuchi, M., Fernandez, M., & Barber, G. N. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8843-8856.2003 · Cited by 215
Treatment of human cancer with mumps virus
Asada, T. (1974) · Cancer · doi:10.1002/1097-0142(197412)34:6<1907::aid-cncr2820340609>3.0.co;2-4 · Cited by 213
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
Devaud, C., John, L. B., Westwood, J. A., Darcy, P. K., & Kershaw, M. H. (2013) · OncoImmunology · doi:10.4161/onci.25961 · Cited by 207
Guedan, S., Rojas, J. J., Gros, A., Mercade, E., Cascallo, M., & Alemany, R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.79 · Cited by 204
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
Workenhe, S. T., & Mossman, K. L. (2014) · Molecular Therapy · doi:10.1038/mt.2013.220 · Cited by 203
Vonderheide, R. H., Burg, J. M., Mick, R., Trosko, J. A., Li, D., Shaik, M. N., Tolcher, A. W., & Hamid, O. (2013) · OncoImmunology · doi:10.4161/onci.23033 · Cited by 202
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002409 · Cited by 200
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Self-citationPark, S. H., Breitbach, C. J., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., Moon, A., Mun, J.-H., Sommermann, E. M., Maruri‐Avidal, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.109 · Cited by 195
Epidemiology and outcomes of serious influenza‐related infections in the cancer population
Cooksley, C. D., Avritscher, E. B. C., Bekele, B. N., Rolston, K. V., Geraci, J. M., & Elting, L. S. (2005) · Cancer · doi:10.1002/cncr.21203 · Cited by 191
Karapanagiotou, E. M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M. E., Larkin, J., Syrigos, K. N., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2181 · Cited by 189
Measles virus causes immunogenic cell death in human melanoma
Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V, Scott, K., Peach, H., Phillips, R. M., Bond, J., Pandha, H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2011.205 · Cited by 187
Stem Cell Collection and Gene Transfer in Fanconi Anemia
Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300033 · Cited by 180
Trial Watch: Toll-like receptor agonists for cancer therapy
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 180
Self-citationZeh, H. J., Downs‐Canner, S., McCart, J. A., Guo, Z. S., Rao, U. N. M., Ramalingam, L., Thorne, S. H., Jones, H. L., Kaliński, P., Wieckowski, E. U., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.194 · Cited by 179
Wildner, O., Blaese, R. M., & Morris, J. C. (1999) · PubMed · Cited by 177
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tähtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 177
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Bridle, B. W., Stephenson, K. B., Boudreau, J. E., Koshy, S., Kazdhan, N., Pullenayegum, E., Brunellière, J., Bramson, J. L., Lichty, B. D., & Wan, Y. (2010) · Molecular Therapy · doi:10.1038/mt.2010.98 · Cited by 176
Maraba Virus as a Potent Oncolytic Vaccine Vector
Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.249 · Cited by 173
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 173
Self-citationIntralesional injection of herpes simplex virus 1716 in metastatic melanoma
MacKie, R. M., Stewart, B., & Brown, S. M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04048-4 · Cited by 171
Trial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Self-citationKanerva, A., Zinn, K. R., Chaudhuri, T. R., Lam, J. T., Suzuki, K., Uil, T. G., Hakkarainen, T., Bauerschmitz, G. J., Wang, M., Liu, B., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00200-4 · Cited by 171
Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
Galanis, E., Okuno, S. H., Nascimento, A. G., Lewis, B. D., Lee, R. A., Oliveira, A. M., Sloan, J. A., Atherton, P., Edmonson, J. H., Erlichman, C., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302436 · Cited by 170
Alonso, M. M., Gomez‐Manzano, C., Bekele, B. N., Yung, W. K. A., & Fueyo-Margareto, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5312 · Cited by 170
Galanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 168
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
Ilkow, C. S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V. A., Boileau, M., Bellamy, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3848 · Cited by 165
Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 165
Geevarghese, S. K., Geller, D. A., de Haan, H. A., Hörer, M., Knoll, A. E., Mescheder, A., Nemunaitis, J., Reid, T. R., Sze, D. Y., Tanabe, K. K., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.020 · Cited by 163
Diaconu, I., Cerullo, V., Hirvinen, M. L. M., Escutenaire, S., Ugolini, M., Pesonen, S. K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A. S. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2975 · Cited by 162
Hwang, T.-H., Moon, A., Burke, J., Ribas, A., Stephenson, J., Breitbach, C. J., Daneshmand, M., De Silva, N., Parato, K., Diallo, J.-S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.132 · Cited by 159
Cripe, T. P., Ngo, M. C., Geller, J. I., Louis, C. U., Currier, M. A., Racadio, J. M., Towbin, A. J., Rooney, C. M., Pelusio, A., Moon, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.243 · Cited by 159
Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J. R., Leuchs, B., Dahm, M., Krebs, O., Doeberitz, M. V. K., Huber, B., & Hajda, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-99 · Cited by 159
Illicit survival of cancer cells during polyploidization and depolyploidization
Vitale, I., Galluzzi, L., Senovilla, L., Criollo, A., Jemaà, M., Castedo, M., & Kroemer, G. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.145 · Cited by 159
Self-citationKrishnamurthy, S., Takimoto, T., Scroggs, R. A., & Portner, A. (2006) · Journal of Virology · doi:10.1128/jvi.02618-05 · Cited by 158
Kicielinski, K. P., Chiocca, E. A., Yu, J. S., Gill, G. M., Coffey, M., & Markert, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.21 · Cited by 158
Shafren, D. R., Au, G. G., Nguyen, T. P., Newcombe, N. G., Haley, E. S., Beagley, L., Johansson, E., Hersey, P., & Barry, R. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0690-3 · Cited by 158
Chemical control of protein stability and function in living mice
Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J., & Thorne, S. H. (2008) · Nature Medicine · doi:10.1038/nm.1754 · Cited by 155
Ikeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4765-4775.2000 · Cited by 154
Gil, M., Komorowski, M. P., Seshadri, M., Rokita, H., McGray, A. R., Opyrchal, M., Odunsi, K. O., & Kozbor, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400201 · Cited by 153
A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication
Edge, R. E., Falls, T. J., Brown, C. W., Lichty, B. D., Atkins, H. L., & Bell, J. C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.130 · Cited by 153
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Self-citationSiveen, K. S., Mustafa, N. B., Li, F., Kannaiyan, R., Ahn, K. S., Kumar, A. P., Chng, W. J., & Sethi, G. (2013) · Oncotarget · doi:10.18632/oncotarget.1596 · Cited by 152
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 150
Self-citationGil, M., Seshadri, M., Komorowski, M. P., Abrams, S. I., & Kozbor, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220580110 · Cited by 147
Mader, E. K., Butler, G. W., Dowdy, S. C., Mariani, A., Knutson, K. L., Federspiel, M. J., Russell, S. J., Galanis, E., Dietz, A. B., & Peng, K.-W. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-20 · Cited by 147
Smac mimetics and innate immune stimuli synergize to promote tumor death
Beug, S. T., Tang, V. A., LaCasse, E. C., Cheung, H. H., Beauregard, C. E., Brun, J., Nuyens, J. P., Earl, N., St-Jean, M., Holbrook, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2806 · Cited by 146
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Hamid, O., Varterasian, M. L., Wadler, S., Hecht, J. R., Benson, A. B., Galanis, E., Uprichard, M. J., Omer, C. A., Bycott, P. W., Hackman, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.114 · Cited by 146
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Rojas, J. J., Sampath, P., Hou, W., & Thorne, S. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2009 · Cited by 144
Guillerme, J.-B., Boisgerault, N., Roulois, D., Ménager, J., Combredet, C., Tangy, F., Fonteneau, J., & Grégoire, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2733 · Cited by 142
Trial watch: Cardiac glycosides and cancer therapy
Menger, L., Vacchelli, E., Kepp, O., Eggermont, A. M. M., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23082 · Cited by 141
Self-citationSpecific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus
Bach, P., Abel, T., Hoffmann, C. M., Gal, Z., Braun, G., Voelker, I., Ball, C. R., Johnston, I., Lauer, U. M., Herold‐Mende, C. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2221 · Cited by 141
Pesonen, S. A., Diaconu, I., Kangasniemi, L., Ranki, T., Kanerva, A., Pesonen, S. K., Gerdemann, U., Leen, A. M., Kairemo, K., Oksanen, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3001 · Cited by 140
Ostertag, D. G., Amundson, K., Espinoza, F. L., Martin, B., Buckley, T., da Silva, A. P., Lin, A. H., Valenta, D. T., Perez, O. D., Ibañez, C. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor199 · Cited by 139
Immunogenic cell death in radiation therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.26536 · Cited by 138
Self-citationPerez, O. D., Logg, C. R., Hiraoka, K., Diago, O. R., Burnett, R., Inagaki, A., Jolson, D., Amundson, K., Buckley, T., Lohse, D., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.83 · Cited by 137
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 136
Self-citationUchida, H., Marzulli, M., Nakano, K., Goins, W. F., Chan, J., Hong, C., Mazzacurati, L., Yoo, J. Y., Haseley, A., Nakashima, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.211 · Cited by 133
Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer
Poirier, J. T., Dobromilskaya, I., Moriarty, W. F., Peacock, C. D., Hann, C. L., & Rudin, C. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt130 · Cited by 133
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.2.19026 · Cited by 132
Self-citationA novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
Post, D. E., & Meir, E. G. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206464 · Cited by 131
Mao, X., Gonzalez, P., Li, C., Meng, G., Jiang, A., Wang, H., Gao, Q., Debatin, K., Beltinger, C. P., & Wei, J. (2014) · Journal of Virology · doi:10.1128/jvi.03851-13 · Cited by 131
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
Wilson, J. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1014 · Cited by 130
Colombo, F., Barzon, L., Franchin, E., Pacenti, M., Pinna, V., Danieli, D., Zanusso, M., & Palù, G. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700851 · Cited by 129
Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting
Kelly, E. J., Nace, R. A., Barber, G. N., & Russell, S. J. (2009) · Journal of Virology · doi:10.1128/jvi.01788-09 · Cited by 129
Alonso, M. M., Jiang, H., Yokoyama, T., Xu, J., Bekele, N. B., Lang, F. F., Kondo, S., Gomez‐Manzano, C., & Fueyo-Margareto, J. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300400 · Cited by 126
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 126
Self-citationErlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Boehrer, S., Adès, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., Roux, G. L., Gardin, C., Martin, A., de Botton, S., et al. (2007) · Blood · doi:10.1182/blood-2007-07-100362 · Cited by 124
Self-citationGanly, I., Eckhardt, S. G., Rodriguez, G. I., et al. (2000) · Clinical Cancer Research · Cited by 123
Workenhe, S. T., Simmons, G., Pol, J. G., Lichty, B. D., Halford, W. P., & Mossman, K. L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.238 · Cited by 122
Canine parvovirus-like particles, a novel nanomaterial for tumor targeting
Singh, P. N. P., Destito, G., Schneemann, A., & Manchester, M. (2006) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-4-2 · Cited by 120
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
Péré, H., Tanchot, C., Bayry, J., Terme, M., Taïeb, J., Badoual, C., Adotévi, O., Merillon, N., Marcheteau, E., Quillien, V., et al. (2012) · OncoImmunology · doi:10.4161/onci.18852 · Cited by 120
Self-citationTrial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 119
Self-citationCascalló, M., Alonso, M. M., Rojas, J. J., Pérez, A., Fueyo-Margareto, J., & Alemany, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300239 · Cited by 118
Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874467210801010013 · Cited by 118
Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., & Barry, M. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.028 · Cited by 116
DIVISION OF MICROBIOLOGY: PRESENT STATUS OF ONCOLYTIC VIRUS STUDIES*
Southam, C. M. (1960) · Transactions of the New York Academy of Sciences · doi:10.1111/j.2164-0947.1960.tb00739.x · Cited by 115
Reid, T. R., Freeman, S., Post, L. E., McCormick, F. P., & Sze, D. Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700819 · Cited by 115
Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.
Kucharczuk, J. C., Randazzo, B. P., Chang, M. Y., Amin, K. M., Elshami, A. A., Sterman, D. H., Rizk, N. P., Molnar-Kimber, K. L., Brown, S. M., MacLean, A. R., et al. (1997) · PubMed · Cited by 115
Morris, D. G., Feng, X., Difrancesco, L., Fonseca, K., Forsyth, P. A., Paterson, A. H. G., Coffey, M. C., & Thompson, B. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9865-z · Cited by 113
Bridle, B. W., Boudreau, J. E., Lichty, B. D., Brunellière, J., Stephenson, K. B., Koshy, S. T., Bramson, J. L., & Wan, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2009.154 · Cited by 111
Muik, A., Kneiske, I., Werbizki, M., Wilflingseder, D., Giroglou, T., Ebert, O., Kraft, A., Dietrich, U., Zimmer, G., Momma, S., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02511-10 · Cited by 111
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Trial Watch: DNA vaccines for cancer therapy
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 110
Self-citationFoloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 110
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J., Pol, J. G., Nguyen, A., Capretta, A. A., He, R., Bramson, J. L., Bell, J. C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.265 · Cited by 110
Kim, M. K., Breitbach, C. J., Moon, A., Heo, J., Lee, Y. K., Cho, M., Lee, J. W., Kim, S.-G., Kang, D. H., Bell, J. C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005361 · Cited by 110
Kimball, K. J., Preuss, M. A., Barnes, M. N., Wang, M., Siegal, G. P., Wan, W., Kuo, H., Saddekni, S., Stockard, C. R., Grizzle, W. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0791 · Cited by 109
Arulanandam, R., Batenchuk, C., Angarita, F. A., Ottolino‐Perry, K., Cousineau, S. E., Mottashed, A., Burgess, E., Falls, T. J., Silva, N. D., Tsang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.009 · Cited by 108
Harnessing the antitumor potential of macrophages for cancer immunotherapy
Long, K. B., & Beatty, G. L. (2013) · OncoImmunology · doi:10.4161/onci.26860 · Cited by 108
Coukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. Μ., & Molnar-Kimber, K. L. (1999) · PubMed · Cited by 108
Muthana, M., Rodrigues, S., Chen, Y., Welford, A. F., Hughes, R., Tazzyman, S. J., Essand, M., Morrow, F. J., & Lewis, C. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3056 · Cited by 107
Kwon, O.-J., Kang, E., Choi, J.-W., Kim, S. W., & Yun, C. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.030 · Cited by 106
Lun, X., Alain, T., Zemp, F. J., Zhou, H., Rahman, M. M., Hamilton, M. G., McFadden, G., Bell, J. C., Senger, D. L., & Forsyth, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1510 · Cited by 106
Ma, Y., Adjemian, S., Yang, H., Catani, J. P. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., et al. (2013) · OncoImmunology · doi:10.4161/onci.24568 · Cited by 104
Self-citationA Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Sborov, D. W., Nuovo, G. J., Stiff, A. R., Mace, T. A., Lesinski, G. B., Benson, D. M., Efebera, Y. A., Rosko, A. E., Pichiorri, F., Grever, M. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1404 · Cited by 102
Grossardt, C., Engeland, C. E., Bossow, S., Halama, N., Zaoui, K., Leber, M. F., Springfeld, C., Jaeger, D., Kalle, C. V., & Ungerechts, G. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.205 · Cited by 101
Trial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 101
Self-citation
Cited by
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationOncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
Self-citationOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Metadata
- Authors
- Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2013-06
- Volume
- 2
- Issue
- 6
- Pages
- e24612
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2033419482
- Cited by
- 255
- References
- 393
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.